Riluzole, disease stage and survival in ALS

Lancet Neurol. 2018 May;17(5):385-386. doi: 10.1016/S1474-4422(18)30091-7. Epub 2018 Mar 7.

Authors

Thanuja Dharmadasa¹, Matthew C Kiernan²

Affiliations

¹ Brain and Mind Centre, University of Sydney and Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, NSW 2040, Australia.
² Brain and Mind Centre, University of Sydney and Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, NSW 2040, Australia. Electronic address: matthew.kiernan@sydney.edu.au.

PMID: 29525493
DOI: 10.1016/S1474-4422(18)30091-7

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Amyotrophic Lateral Sclerosis*
Humans
Neuroprotective Agents
Retrospective Studies
Riluzole*

Substances

Neuroprotective Agents
Riluzole

Supplementary concepts

Amyotrophic Lateral Sclerosis 2, Juvenile